Moderna Inc (MRNA) stock is lower by -21.86% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver’s proprietary ranking system, gives MRNA stock a score of 73 out of a possible 100.
That rank is chiefly influenced by a fundamental score of 96. In addition to the average rating from Wall Street analysts, MRNA stock has a mean target price of $241.38. This means analysts expect the stock to increase 72.89% over the next 12 months. MRNA's rank also includes a short-term technical score of 64. The long-term technical score for MRNA is 58.
MRNA has an Overall Score of 73. Find out what this means to you and get the rest of the rankings on MRNA!
Moderna Inc (MRNA) stock is lower by -1.97% while the S&P 500 is higher by 0.31% as of 11:01 AM on Thursday, Apr 28. MRNA is lower by -$2.81 from the previous closing price of $142.43 on volume of 1,653,774 shares. Over the past year the S&P 500 has risen 0.32% while MRNA is lower by -21.86%. MRNA earned $28.31 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 4.87.
Click Here to get the full Stock Report for Moderna Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
